A phase 2a clinical trial of NEO100-01 is continuing to recruit patients with malignant gliomas, with full enrollment expected in September.

Classified as malignant or benign, malignant primary brain tumours, such as gliomas and astrocytomas, exhibit uncontrolled growth and can spread, while benign tumours remain localised. In an ...